Diagnosis and management of community-associated MRSA infections in children

Caroline B. Long, Rebecca P. Madan, Betsy Herold

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The history of antibiotic resistance in Staphylococcus aureus spans more than half a century. Methicillin-resistant S. aureus (MRSA) has emerged as an almost ubiquitous pathogen in both the community and hospital settings. The predominant clone responsible for community-associated MRSA, USA300, is a highly successful pathogen, as demonstrated by its rapid global spread and associated morbidity and mortality. The management of MRSA infections in pediatric patients is complicated by the limited number of effective antibiotics that have been well-studied in children. The gold standard antimicrobial, vancomycin, has several shortcomings that have prompted the development of newer agents for the treatment of MRSA disease. Moreover, the emergence of vancomycin-intermediate or -resistant S. aureus, while uncommon, portends a potential new era of resistance that will require research and development of the next generation of antibiotics that act by novel mechanisms.

Original languageEnglish (US)
Pages (from-to)183-195
Number of pages13
JournalExpert Review of Anti-Infective Therapy
Volume8
Issue number2
DOIs
StatePublished - Jan 1 2010

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Vancomycin
Infection
Staphylococcus aureus
Anti-Bacterial Agents
Community Hospital
Microbial Drug Resistance
Clone Cells
History
Pediatrics
Morbidity
Mortality
Research
Therapeutics

Keywords

  • antibiotic management
  • community-associated methicillin resistance
  • pediatric
  • severe infection
  • Staphylococcus aureus
  • vancomycin

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

Diagnosis and management of community-associated MRSA infections in children. / Long, Caroline B.; Madan, Rebecca P.; Herold, Betsy.

In: Expert Review of Anti-Infective Therapy, Vol. 8, No. 2, 01.01.2010, p. 183-195.

Research output: Contribution to journalReview article

@article{a58000126c3e488b846673ac92023aa6,
title = "Diagnosis and management of community-associated MRSA infections in children",
abstract = "The history of antibiotic resistance in Staphylococcus aureus spans more than half a century. Methicillin-resistant S. aureus (MRSA) has emerged as an almost ubiquitous pathogen in both the community and hospital settings. The predominant clone responsible for community-associated MRSA, USA300, is a highly successful pathogen, as demonstrated by its rapid global spread and associated morbidity and mortality. The management of MRSA infections in pediatric patients is complicated by the limited number of effective antibiotics that have been well-studied in children. The gold standard antimicrobial, vancomycin, has several shortcomings that have prompted the development of newer agents for the treatment of MRSA disease. Moreover, the emergence of vancomycin-intermediate or -resistant S. aureus, while uncommon, portends a potential new era of resistance that will require research and development of the next generation of antibiotics that act by novel mechanisms.",
keywords = "antibiotic management, community-associated methicillin resistance, pediatric, severe infection, Staphylococcus aureus, vancomycin",
author = "Long, {Caroline B.} and Madan, {Rebecca P.} and Betsy Herold",
year = "2010",
month = "1",
day = "1",
doi = "10.1586/eri.09.127",
language = "English (US)",
volume = "8",
pages = "183--195",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Diagnosis and management of community-associated MRSA infections in children

AU - Long, Caroline B.

AU - Madan, Rebecca P.

AU - Herold, Betsy

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The history of antibiotic resistance in Staphylococcus aureus spans more than half a century. Methicillin-resistant S. aureus (MRSA) has emerged as an almost ubiquitous pathogen in both the community and hospital settings. The predominant clone responsible for community-associated MRSA, USA300, is a highly successful pathogen, as demonstrated by its rapid global spread and associated morbidity and mortality. The management of MRSA infections in pediatric patients is complicated by the limited number of effective antibiotics that have been well-studied in children. The gold standard antimicrobial, vancomycin, has several shortcomings that have prompted the development of newer agents for the treatment of MRSA disease. Moreover, the emergence of vancomycin-intermediate or -resistant S. aureus, while uncommon, portends a potential new era of resistance that will require research and development of the next generation of antibiotics that act by novel mechanisms.

AB - The history of antibiotic resistance in Staphylococcus aureus spans more than half a century. Methicillin-resistant S. aureus (MRSA) has emerged as an almost ubiquitous pathogen in both the community and hospital settings. The predominant clone responsible for community-associated MRSA, USA300, is a highly successful pathogen, as demonstrated by its rapid global spread and associated morbidity and mortality. The management of MRSA infections in pediatric patients is complicated by the limited number of effective antibiotics that have been well-studied in children. The gold standard antimicrobial, vancomycin, has several shortcomings that have prompted the development of newer agents for the treatment of MRSA disease. Moreover, the emergence of vancomycin-intermediate or -resistant S. aureus, while uncommon, portends a potential new era of resistance that will require research and development of the next generation of antibiotics that act by novel mechanisms.

KW - antibiotic management

KW - community-associated methicillin resistance

KW - pediatric

KW - severe infection

KW - Staphylococcus aureus

KW - vancomycin

UR - http://www.scopus.com/inward/record.url?scp=85047687774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047687774&partnerID=8YFLogxK

U2 - 10.1586/eri.09.127

DO - 10.1586/eri.09.127

M3 - Review article

C2 - 20109048

AN - SCOPUS:85047687774

VL - 8

SP - 183

EP - 195

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 2

ER -